Paper in review - MedRxiv preprint:
Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors.
A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders to cancer treatment.
Serial changes in tumor-derived whole-genome cfDNA fraction to identify early disease progression prior to imaging.
Detection of Somatic Copy Number Aberrations in cfDNAfrom Patients with Solid Tumor Malignancies.
Comparison of bisulfite- and methyl-capture approaches for mapping the cell-free methylome in late-stage cancer patients.